155 related articles for article (PubMed ID: 21590632)
1. [The beta cell in diabetes].
Lenzen S
Dtsch Med Wochenschr; 2011 May; 136(21):1123-7. PubMed ID: 21590632
[No Abstract] [Full Text] [Related]
2. The key to glucose: a guide to the hormone (and protein) insulin.
Gebel E
Diabetes Forecast; 2011 Oct; 64(10):32, 35. PubMed ID: 22010364
[No Abstract] [Full Text] [Related]
3. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
Lupi R; Del Prato S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
[TBL] [Abstract][Full Text] [Related]
4. [Antibodies instead of insulin?].
Anders S; Kühnemund L; Stauch M; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2010 Mar; 39(2):97-8. PubMed ID: 20196056
[No Abstract] [Full Text] [Related]
5. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
[No Abstract] [Full Text] [Related]
6. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
7. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
9. [How to explain the rebirth of the beta cell in terms of sacrifice and delivery].
Halban PA
Journ Annu Diabetol Hotel Dieu; 2007; ():171-9. PubMed ID: 18610768
[No Abstract] [Full Text] [Related]
10. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
11. Glucose regulation of β-cell stress in type 2 diabetes.
Leibowitz G; Bachar E; Shaked M; Sinai A; Ketzinel-Gilad M; Cerasi E; Kaiser N
Diabetes Obes Metab; 2010 Oct; 12 Suppl 2():66-75. PubMed ID: 21029302
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus.
Slama G
Int J Clin Pract Suppl; 2000 Sep; (112):9-12. PubMed ID: 11064945
[No Abstract] [Full Text] [Related]
13. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
14. Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Holloway AC; Hettinga BP; Gerstein HC
J Diabetes; 2011 Mar; 3(1):74-81. PubMed ID: 21040499
[TBL] [Abstract][Full Text] [Related]
15. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
16. [Physical exercise and diabetes. Physiopathologic and clinical aspects].
Trovati M
Minerva Endocrinol; 1986; 11(1):55-60. PubMed ID: 3528802
[No Abstract] [Full Text] [Related]
17. Distinctions between islet neogenesis and β-cell replication: implications for reversal of Type 1 and 2 diabetes.
Levetan C
J Diabetes; 2010 Jun; 2(2):76-84. PubMed ID: 20923488
[TBL] [Abstract][Full Text] [Related]
18. Unexplained improvement in diabetes control: a wolf in sheep's clothing.
Snow KJ
Compr Ther; 1995 Oct; 21(10):590-3. PubMed ID: 8565428
[No Abstract] [Full Text] [Related]
19. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
Xue S; Wasserfall C; Parker M; McGrail S; McGrail K; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
J Diabetes Complications; 2010; 24(3):163-7. PubMed ID: 19217320
[TBL] [Abstract][Full Text] [Related]
20. Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
Donath MY; Schumann DM; Faulenbach M; Ellingsgaard H; Perren A; Ehses JA
Diabetes Care; 2008 Feb; 31 Suppl 2():S161-4. PubMed ID: 18227479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
